GlobeNewswire EN Nachrichten

 

Alkane Executes $110 Million Revolving Credit Facility...

BEIJING, March 29, 2026 (GLOBE NEWSWIRE) -- Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of China's leading and fastest-growing lifecycle automotive service and supply-chain technology platforms, announced today that it has received a written notification (the "Notification Letter") from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 25, 2026 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities (“MVLS”) of US$50,000,000 set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market, as its MVLS for the 30 consecutive business days from February 10, 2026 to March 24, 2026 has failed to meet the minimum requirement. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until September 21, 2026, to regain compliance. If at any time during this compliance period the Company's MVLS closes at US$50,000,000 or mo...

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1.The results were published in the New England Journal of Medicine and simultaneously presented as late‑breaking data at the 2026 World Congress of Nephrology (WCN)....

CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), which has the potential to become the first innovative therapy approved for CLE in 70 years. Part A of AMETHYST evaluated the efficacy and safety of litifilimab through week 24, with reductions in skin disease activity reported across several measures. Results are consistent with the earlier positive Phase 2 LILAC study reported in The New England Journal of Medicine. Phase 2 results from LILAC and AMETHYST supported litifilimab's recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation. Results are being presented today at the American Academy of Dermatology (AAD) Annual Meeting....

ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the data at the 2026 American Academy of Dermatology (AAD) Annual Meeting later today....

DURHAM, N.C., March 28, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics, a clinical-stage biotechnology company focused on developing targeted therapeutics in autoimmune disease, announced today the publication of results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis (DM) in the New England Journal of Medicine (NEJM)....

Decision of the US District Court for the Southern District of New York in the TriZetto re-trial...

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials...

TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF (the “Fund”) (formerly Mulvihill U.S. Health Care Enhanced Yield ETF) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of units amounted to $0.67 million or $0.31 per unit. As at December 31, 2025, net assets attributable to holders of units were $25.29 million or $9.36 per unit. Cash distributions to unitholders totaling $2.26 million or $1.00 per unit were paid during the year....

TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: PGIC; PGIC.PR.A)  (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of Class A shares amounted to $3.62 million or $1.32 per Class A share.   As at December 31, 2025, net assets attributable to holders of Class A shares were $25.69 million or $6.77 per Class A share. Cash distributions of $0.75 per Preferred share and $0.96 per Class A share were paid during the year....

TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: MPY) Mulvihill Premium Yield Fund (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of Class I units amounted to $1.29 million or $1.10 per Class I unit, increase in net assets attributable to holders of Class F units amounted to $1.25 million or $1.13 per Class F unit,   increase in net assets attributable to holders of Class A units amounted to $0.40 million or $0.46 per Class A unit, and increase in net assets attributable to holders of ETF units amounted to $0.84 million or $0.55 per ETF unit. As at December 31, 2025, net assets attributable to holders of Class I were $12.67 million or $10.93 per Class I unit; net assets attributable to holders of Class F were $12.62 million or $10.94 per Class F unit, net assets attributable to holders of Class A units were $7.21 million or $10.08 per Class A unit, and net asset attributable to holders of ETF units were $15.32 mill...

TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF (the “Fund”) announces results of operations for the year ended December 31, 2025. Increase in net assets attributable to holders of units amounted to $47.04 million or $3.75 per unit. As at December 31, 2025, net assets attributable to holders of units were $130.48 million or $11.86 per unit. Cash distributions to unitholders totaling $8.67 million or $0.70 per unit were paid during the year....

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at 2026 AAD...

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session...

Rocket Lab successfully launched a pair of satellites for the European Space Agency (ESA) to test new navigation systems in low Earth orbit....

New data analyses from the Company's varoglutamstat Phase 2 program were presented at the World Congress of Nephrology....

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise)...

Miata Metals Announces Grant of Stock Options...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES....